

UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

| | | |
|-----------------------------|---|---------------------|
| HOSPIRA, INC. |) | |
| |) | |
| Plaintiff, |) | |
| |) | |
| v. |) | |
| |) | C.A. No. 15-697-RGA |
| AMNEAL PHARMACEUTICALS, LLC |) | |
| |) | |
| Defendant. |) | |

JOINT ADMITTED TRIAL EXHIBIT LIST

| | | |
|--|--|---|
| PRESIDING JUDGE The Honorable Judge Richard G. Andrews | PLAINTIFF'S ATTORNEY Jenner & Block LLP Connolly Gallagher LLP | DEFENDANT'S ATTORNEY Maddox Edwards PLLC Richards, Layton & Finger, P.A. |
| TRIAL DATE(S) August 21 – August 24, 2017 | COURT REPORTER Valerie Gunning | |

| EX. NO. | DESCRIPTION OF EXHIBITS |
|---------|---|
| JTX 001 | U.S. Patent No. 8,242,158 |
| JTX 002 | U.S. Patent No. 8,338,470 |
| JTX 003 | U.S. Patent No. 8,455,527 |
| JTX 004 | U.S. Patent No. 8,648,106 |
| JTX 017 | Precedex Pre-Mix Research Deck |
| JTX 022 | Letter to customer re Precedex Premix approval |
| JTX 025 | Precedex Qualitative Market Research Deck |
| JTX 026 | Hospira Product Development Concept Proposal |
| JTX 027 | Precedex Line Extension Meeting Minutes |
| JTX 049 | Ex. A of Opening Expert Report of Michael Ramsay - CV |
| JTX 052 | Ex. A of Opening Expert Report of Robert Linhardt, Ph.D. - CV |
| JTX 056 | Amneal ANDA 3.2.P.8.3 Stability Report for Accelerated and Long Term Conditions |
| JTX 063 | Sales data through Q2 2016 |
| JTX 064 | Precedex Premix Value Proposition Evaluation |
| JTX 066 | Staging Precedex Premix Conversions |
| JTX 068 | Precedex margin and price data |
| JTX 069 | Precedex Premix Launch Readiness Review |
| JTX 071 | Precedex Premix Deck |
| JTX 073 | K. Kumar, Linear and non-linear regression analysis for the sorption kinetics of methylene blue onto activated carbon, JOURNAL OF HAZARDOUS MATERIALS pp. 1538-44 (Apr. 2006) |

| EX. NO. | DESCRIPTION OF EXHIBITS |
|----------------|---|
| JTX 074 | R. Matthews, Photooxidative degradation of coloured organics in water using supported catalysts, 25(10) WATER RESEARCH 1169-76 (1991) |
| JTX 076 | Amneal ANDA Section 3.2.P.5.1 Finished Product Specification |
| JTX 083 | Defendant Amneal Pharmaceuticals LLC's Response to Plaintiff's First Requests for the Production of Documents and Things (Nos. 1-37) |
| JTX 093 | Laboratory Notebook - 02282 |
| JTX 095 | Laboratory Notebook Excerpt - 00737 |
| JTX 096 | Laboratory Notebook Excerpt - 00738 |
| PTX 005 | File History of U.S. Patent No. 8,242,158 |
| PTX 006 | File History of U.S. Patent No. 8,338,470 |
| PTX 007 | File History of U.S. Patent No. 8,455,527 |
| PTX 008 | File History of U.S. Patent No. 8,648,106 |
| PTX 031 | Launch of Premixed Precedex Market research findings report Deck |
| PTX 040 | Development Report for Precedex LE Injection Rev 1.0 authored by Roychowdhury |
| PTX 063 | Amneal ANDA Section 2.3 Quality (CMC) Overall Summary |
| PTX 064 | Amneal ANDA Section 3.2.P.7 Container Closure System |
| PTX 065 | Amneal ANDA Section 3.2.P.2 Pharmaceutical Development |
| PTX 071 | FDA Memorandum by Cynthia G. McCormick, M.D. |
| PTX 092 | Amneal ANDA 3.2.P.8.3 Stability Report for Accelerated and Long Term Conditions |
| PTX 093 | Amneal ANDA Stability Protocol |
| PTX 095 | Y. Wang, Sterile Pharmaceutical Packaging: Compatibility and Stability |
| PTX 122 | Development Report for Precedex Injection 4 mcg-mL initiated by Skora Rev 2.0 |
| PTX 143 | Laboratory Notebook - 01123 |
| PTX 144 | Laboratory Notebook - 01539 |
| PTX 146 | Laboratory Notebook - 01729 |
| PTX 204 | Precedex Marketing costs |
| PTX 214 | October 1, 2014, Declaration of Alpaslan Yaman, Ph.D. (IPR Pet. for Pat. No. 7,659,291) |
| DTX 003 | Cain, J., Dexmedetomidine and Hextend: Their Role in Trauma Care, International TraumaCare, Vol 17, No. 1, 4-5 (2007) |
| DTX 023 | Precedex® Label (2010) |
| DTX 024 | Ramsay, M., et al., Dexmedetomidine as a total intravenous anesthetic agent, Anesthesiology, Vol. 101, No. 3, 787-790 (2004) |
| DTX 043 | Eichhorn, J., APSF Hosts Medication Safety Conference, APSF Newsletter, Vol. 25, No. 1, 1-20 (2010) |
| DTX 044 | Fanikos, J., Premixed Products Improve Safe Medication Practices, Pharmacy Practice News, 56-57 (November 2011) |
| DTX 046 | Giorgi, I., et al., Risk and pharmacoeconomic analyses of the injectable medication process in the paediatric and neonatal intensive care units, International Journal for Quality in Health Care, Vol. 22, No. 3, 170-178 (2010) |
| DTX 063 | Palmgrén, J., et al., Drug adsorption to plastic containers and retention of drugs |

| EX. NO. | DESCRIPTION OF EXHIBITS |
|----------------|---|
| | in cultured cells under in vitro conditions, European Journal of Pharmaceutics and Biopharmaceutics, Vol. 64, 369-378 (2006) |
| DTX 073 | U.S. Patent No. 4,910,214 (Karjalainen) |
| DTX 086 | Anneal's Module 3-2-P-8-3 – Stability Report |
| DTX 095 | Hospira's Module 3-2-P-2-2-1 – Drug Product, Formulation Development |
| DTX 102 | Anes, Use of Plastics for Parenteral Packaging |
| DTX 104 | Avis, K. (ed.), Pharmaceutical Dosage Forms: Parenteral Medications, Volume 1, 2nd ed., 161 |
| DTX 108 | FDA Memorandum from McCormick to Jenkins |
| DTX 111 | Linden, P., et al., Ready-to-use Injection Preparations versus Conventional Reconstituted Admixtures, Pharmacoconomics, Vol. 20, No. 8, 529-536 (2002) |
| DTX 113 | Hospira Scientific Report – Precedex Stability Data to Support Qualifications of the Product in a 20 mL glass vial |
| DTX 114 | IND 32,934 - Letter to FDA from Azarnoff (5-23-94) |
| DTX 120 | Trissel, L., et al., Compatibility Screening of Precedex During Simulated Y-Site Administration with Other Drugs, International Journal of Pharmaceutical Compounding, Vol. 6, No. 3 (2002) |
| DTX 191 | Hospira, Inc.'s Responses to Anneal's Second Set Of Interrogatories (Nos. 7-23) |
| DTX 199 | Abbott IND excerpt dexmedetomidine (3-17-1989) |
| DTX 200 | Akers, Sterile Drug Products: Formulation, Packaging, Manufacturing, and Quality, Ch. 7, "Sterile Products Packaging Chemistry" at 72-95 (2010) |
| DTX 201 | Avis, K. (ed.), Sterile Pharmaceutical Products: Process Engineering Applications, 297, 300, 380, and 389 (1995) |
| DTX 202 | Bauer, E., Pharmaceutical Packaging Handbook, ch. 6, Pharmaceutical Packaging Materials, 189-272 (2009) |
| DTX 203 | Development Report for Precedex Injection - Hospira Scientific Report (4-2-2010) |
| DTX 206 | Hospira Scientific Report - Precedex LE |
| DTX 207 | ICH Harmonised Tripartite Guideline, Stability Testing of New Drug Substances and Products - Q1A(R2) (February 6, 2003) |
| DTX 208 | Linhardt Opening Expert Report |
| DTX 209 | Morrison and Boyd, Organic Chemistry, 6th ed., 136-138 (1992) |
| DTX 210 | Nema, S., et al. (ed.), Pharmaceutical Dosage Forms: Parenteral Medications, 3rd ed., Vol. 3: Regulations, Validation and the Future, (2010) (excerpts) |
| DTX 213 | Precedex Life Cycle Management Strategy Session (11-7-2006) |
| DTX 214 | Precedex Line Extension Meeting Minutes (2-2-2007) |
| DTX 216 | Precedex Line Extension Meeting Minutes (5-18-2007 and 5-25-2007) |
| DTX 219 | Sacha, G., et al., Practical fundamentals of glass, rubber, and plastic sterile packaging systems, Pharmaceutical Development and Technology, Vol. 15, No. 1, 6-34 (2010) |
| DTX 231 | Email chain re Precedex Overview |
| DTX 246 | Hospira SEC Form 10-K (fiscal year ending 12-31-2012) |
| DTX 247 | Hospira SEC Form 10-K (fiscal year ending 12-31-2013) |

| EX. NO. | DESCRIPTION OF EXHIBITS |
|----------------|--|
| DTX 248 | Hospira SEC Form 10-K (fiscal year ending 12-31-2014) |
| DTX 301 | Hospira Presentation, "Precedex Business Overview with Orion Pharma" |
| DTX 315 | Hospira Presentation, "Precedex/Propofol Deal Strategy" |
| DTX 416 | Orange Book - Patent and Exclusivity for NDA 021038 |
| DTX 426 | Presentation - Precedex US Commercial Deep Dive (8-22-2012) |
| DTX 434 | Erkola, O., et al., Comparison of Intramuscular Dexmedetomidine and Midazolam Premedication for Elective Abdominal Hysterectomy, Anesth. Analg., Vol. 79, 646-653 (1994) |
| DTX 458 | Amneal's Notice of 30(b)(6) Deposition of Hospira |
| DTX 469 | Precedex Prescribing information (03-2008) |
| DTX 472 | NDA Module 3 - 3-2-P-8-3 – Stability Data |
| DTX 478 | Joint Appendix in Hospira v Fresenius - NDIL |
| DTX 486 | Linhardt Reply Expert Report |
| DTX 495 | S. Yoshioka, Stability of Drugs and Dosage Forms § 4.4 (2000) |
| DTX 516 | Bloch Curriculum Vitae (CV) |
| DTX 517 | Hofmann Curriculum Vitae (CV) |
| DTX 518 | Yaman Curriculum Vitae (CV) |
| DTX 533 | Physical Sample of Precedex Premix Vial |
| DTX 534 | Physical Sample of Precedex Concentrate Vial |
| DTX 535 | Trissel, L., Handbook on Injectable Drugs, 16th ed. (2011) (excerpts) [updated] |
| DTX 537 | Cain Curriculum Vitae (CV) (updated) |
| DTX 551 | Hospira Stability Data |
| DTX 553 | Akers, M., Parenteral Preparations, Remington's Pharmaceutical Sciences 802-836 (2006, 21st ed.) |